Subscribe
1 August 2024NewsAmericasMuireann Bolger

Teva asks Fed Circ to reverse inhaler patents loss

Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks